Physician

Julia A. Cogburn, M.D.

According to 2025 Medicare claims, Julia Cogburn, M.D. (NPI: 1245439702) practices internal medicine in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33613-4679.

Cogburn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 621 traditional Medicare patients, billed 169,930 HCPCS/CPT codes, and received $2,350,172 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,384 prescription claims across 223 beneficiaries totaling $2,312,989 in drug costs, led by Ibrance (Palbociclib). 2022 DME data shows 11 claims. Open Payments data shows 196 records totaling $5,162. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $350,163 to $2,312,989. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	942	165,940	$1,828,891
2016	968	134,816	$1,504,967
2017	994	204,906	$2,363,780
2018	982	199,450	$2,286,343
2019	1,179	179,711	$2,254,729
2020	915	189,783	$2,114,902
2021	878	168,659	$2,044,632
2022	761	186,476	$1,918,100
2023	700	171,428	$2,003,854
2024	621	169,930	$2,350,172

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	154	792	$350,163
2016	134	797	$583,006
2017	156	955	$869,869
2018	171	875	$708,228
2019	175	894	$1,301,515
2020	164	967	$1,508,857
2021	194	1,176	$1,886,171
2022	198	1,134	$2,212,475
2023	216	1,151	$1,640,733
2024	223	1,384	$2,312,989

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$1,052
2016	N/R	37	$2,199
2017	N/R	49	$8,314
2018	N/R	12	$1,557
2019	N/R	N/R	N/R
2020	N/R	13	$1,631
2021	N/R	13	$985
2022	N/R	11	$402
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	241	561	$93
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	209	325	$13
96372	Injection of drug or substance under skin or into muscle	143	630	$10
36415	Insertion of needle into vein for collection of blood sample	413	1,132	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	446	1,309	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	21	588	$338,995
Tagrisso	Osimertinib Mesylate	17	510	$280,848
Revlimid	Lenalidomide	15	420	$267,331
Jakafi	Ruxolitinib Phosphate	12	360	$207,555
Kisqali	Ribociclib Succinate	14	392	$203,051

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	196	$5,162	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Julia A. Cogburn, M.D.?

Tedicare shows public-source Medicare data for Julia A. Cogburn, M.D. (NPI 1245439702), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Julia A. Cogburn, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Julia A. Cogburn, M.D.?

Julia A. Cogburn, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Julia A. Cogburn, M.D. have Open Payments data?

Julia A. Cogburn, M.D. has 196 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.